The largest community for pharma industry

Contributors

Preparing for take-off: a ticket to first class MCM planning

by Jan Keuppens “Omnichannel strategist / head of Marketing” @ Across health You wouldn’t attempt to fly a plane without first understanding all the controls and...

Rare Diseases at Roche: Combining science and alliances to find breakthroughs in rare diseases

One of the biggest events in the rare disease calendar – the Huntington Disease Society of America annual convention – is taking place this week, the...

Five Essential Skills for Pharma’s Future Leaders

By Steve Figman, Syntegrity The recent eyeforpharma ‘19 conference in Philadelphia showcased an impressive array of speakers, with presentations and roundtable discussions from thought leaders...

Why Too Many Clinical Trials Fail

By Julien Moussalli Market Expansion Lead at IQVIA (LinkedIn: https://www.linkedin.com/in/julien-moussalli-80010349/) A makeover of the $65 billion clinical trials market (1) is well overdue. According to...

A Pharmaceutical Launch Opportunity:​ Science, Art or Alchemy?

A publisher friend recently suggested I write down what I knew about launching pharmaceutical brands, to help new marketers who may have been handed...

How you can add value to your self-inspection programme

by Lorraine Lyons. Pharmaceutical Quality Consultant and Qualified Person (QP) with over 16 years’ experience in the Pharmaceutical Industry. Self-inspections support an organisation in accomplishing its...

Change Medical Reps Status from ‘Unwelcomed’​ to ‘Most Welcome’​

Just a decade ago, the job of a pharma sales rep was much desired among pharma professionals. DTC advertising did most of the heavy...

Improving The Communication Between Drug Reps and Doctors

What does it mean to be a drug rep / medical representative? What is this magical profession about, that forces all managers, executives and...

Addition by Subtraction

Addition by Subtraction? Sounds paradoxical? Unbelievable? Consider what Lao Tzu, the great Chinese philosopher said 2,500 years ago. Here is the essence of what he said: To attain knowledge, add things everyday. To attain wisdom, subtract things everyday. Profit comes from what is there, and usefulness comes from what is not there.

Is there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?

By Dr. Jonathan Trethowan, Vice President Regulatory and Scientific Policy at PharmaLex Every month, there are 45 million patient packs of medicines transported from the...

Gene Editing in the UK Parliament

Published on November 22, 2018 Pic: From right to left: Ms Nunzia Florio (External Affairs Manager at BIVDA); Lord Warner (Crossbench, Minister of Health from 2005 to 2007); yours truly;...

Corporate Career Management – A Right Now Perspective

It would be great to be one of those people who knew, from an early age, exactly what they wanted to be when they...

Recent Featured Articles

Bien-Etre Labs Achieves Seven Million Dollars ($7M) Investment Funding

HIGH POINT, N.C.--(BUSINESS WIRE)--Bien-Etre Labs, (www.bienetre.com) a nutraceutical research, discovery and development company focusing on pre- and probiotic products to regulate the human biome,...

Merck Announces Appointment of Organon & Co. General Counsel

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Deborah H. Telman as General...

ProteinQure Collaborates with AstraZeneca to Design Novel Peptide Therapeutics

TORONTO--(BUSINESS WIRE)--ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the...

LGC Acquires The Native Antigen Company, Strengthening its Offer to the IVD Sector

LONDON & OXFORD, England--(BUSINESS WIRE)--Today, LGC announced the acquisition of The Native Antigen Company (NAC), one of the world’s leading suppliers of high quality...

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases, today...